fbpx

Monopar Therapeutics Inc

MNPR

$22.01

Closing

▼-2.31%

1D

▲1194.71%

YTD

MNPR

BBG00J7K8DB7

Exchange

Sector

Market cap

$117.69M

Volume

9,443

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$117.69M

Analysts' Rating

BUY

Price Target (Mean)

18.00

Total Analysts

3

P/E

Operating Margin

0.00%

Beta

1.20

Revenue Growth

0.00%

52 week high

$38.50

52 week low

$1.40

Div. Yield

%

EPS Growth

0.00

Company Profile

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.